27 Jan 2022
Moderna Commences Trial for Potential Omicron Booster Shot
The Index Today
Moderna Inc. on Wednesday announced that it has begun testing a potential booster vaccine specifically aimed at tackling the Omicron variant of COVID-19. This comes after Pfizer started similar vaccine trials to protect against the highly contagious variant.
Although the Omicron is a comparatively milder version of the coronavirus, it has been spreading rapidly leading to mounting infection rates that increase pressure on the healthcare systems across the world. At the moment, 99.9% cases of COVID-19 are reported to be Omicron-related.
Moderna is planning on running the study on 300 participants aged 18 years and above who will be divided into two groups. The test would be conducted on individuals who have received just two doses of its primary mRNA-1273 vaccine.
This comes as three separate studies conducted by the Centers for Disease Control and Prevention (CDC) in the U.S. found that a third dose of the mRNA vaccine by either Moderna or Pfizer is essential in protecting against the Omicron.
©Photo: Bodo Schackow/dpa via AP